Ken リクルターブログ

• Hormone Replacement Therapies Can Help Women with Bothersome Menopausal Symptoms
• Advisory Committees Give FDA Critical Advice and the Public a Voice
• The Facts on Tampons and Tampon Safety
• Tips to Stay Safe in the Sun: From Sunscreen to Sunglasses
• Should You Put Sunscreen on Infants? Not Usually

• 香港に美の季節が到来！アジア最大の美容ウィーク、一足先にサプライチェーンに特化した「COSMOPACK ASIA 2026」が開幕
• 【ウコン】ドリンクが牽引、マーケットサイズ200億円台に回復
• 【抗糖化】美容からロンジェビティ領域への提案広がる
• 【販促・営業支援】多様化ニーズに伴走して応える“強い味方”
• 【オーガニック&ナチュラル】オーガニック×ナチュラルが切り拓く新市場

• FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition
• FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy
• Eugia US LLC Issues Recall of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) Due to Presence of Particulate Matter
• Counterfeit Versions of Eye Drops Found in Several States
• Par Health Issues Voluntary Nationwide Recall of Argatroban Injection Due to the Presence of Particulate Matter

• uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for Ifezuntirgene Inilparvovec for the Treatment of Huntington’s Disease
• Orexo Announces FDA Acceptance of Izipry™ NDA Resubmission for Review
• Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C
• Alume Biosciences Announces FDA Acceptance of New Drug Application for Bevonescein for Use During Surgery
• AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma

• IQVIAジャパン　2031年度までの薬価収載品市場は＋2.3％成長　イノベーション推進が成長の後押…
• エーザイ・内藤CEO　レケンビの市場拡大に自信　皮下注製剤上市で導入施設拡大に「大きな打開を期待」
• メディパルHD・今川社長　高度物流・ＭＲ機能や“推奨後発品”で仕入原価「コントロールしていく」
• アルフレッサHD・荒川社長　「ネオプライマリー戦略」で診療所販路が市場平均成長率を上回る成果実現
• 杏林製薬・荻原社長　26年度は営業赤字49億円の見通し　積極的な開発品導入で　「委縮せず戦略進める」

MR patio